Mary Shago

Mary Shago

Auto-generated profile, based on publicly available information

Mary Shago

Department of Laboratory Medicine and Pathobiology University of Toronto Toronto Ontario Canada

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2018 in Science
Verified
Journal Article
Closed access
PDF file
NANathaniel D. Anderson
Nathaniel D. Anderson
RBRichard de Borja
Richard de Borja
MYMatthew D. Young
Matthew D. Young
FFFabio Fuligni
Fabio Fuligni
ARAndrej Rosic
Andrej Rosic
ASAdam Shlien
Adam Shlien
Looping together genes in cancer: A subset of human cancers are characterized by aberrant fusion of two specific genes. In some cases, the activity of the resultant fusion protein drives tumor growth. Most fusion genes in cancer appear to arise from simple reciprocal chromosomal translocations. Anderson et al. found that the characteristic fusion gene in a bone and soft tissue tumor called Ewing sarcoma is produced by a far more complicated mechanism (see the Perspective by Imielinski and Ladanyi). In nearly half of the tumors examined, the fusion gene was created by the formation of dramatic genomic loops that disrupt multiple genes. These complex rearrangements occur in early replicating and transcriptionally active regions of the genome and are associated with poor prognosis. Science , this issue p. eaam8419 ; see also p. 848

15 September 2011 in Acta Neuropathologica
Verified
Journal Article
Closed access
GIGeorge M. Ibrahim
George M. Ibrahim
AHAnnie Huang
Annie Huang
WHWilliam Halliday
William Halliday
PDPeter B. Dirks
Peter B. Dirks
DMDavid Malkin
David Malkin
CHCynthia Hawkins
Cynthia Hawkins

1 July 2010 in Pediatric and Developmental Pathology
Verified
Journal Article
Closed access
KCKenneth Tou-En Chang
Kenneth Tou-En Chang
NCNeil K. Chadha
Neil K. Chadha
RLRichard Leung
Richard Leung
MSMary Shago
Mary Shago
MPM. James Phillips
M. James Phillips
PTPaul S. Thorner
Paul S. Thorner
Lymphadenoma of the salivary gland is a rare benign tumor with only 11 reported cases in the English language literature, most of which have occurred in adults. We report a case of a lymphadenoma occurring in the parotid gland of a 15-year-old girl. The tumor was composed of variably sized cystic cavities within abundant reactive lymphoid tissue. The cystic spaces were filled with eosinophilic secretions with occasional histiocytes. Many of these features were also apparent on cytologic preparations. The cysts were lined by epithelium lacking atypia and showed luminal and abluminal differentiation both by immunohistochemistry and by electron microscopy. Tumor cells were not cycling as determined by MIB1 immunostaining, and the tumor karyotype was normal. This is only the second case to be reported in the pediatric age group. Ultrastructural features and karyotype analysis are reported for the first time. Although this tumor is rarely encountered by pediatric pathologists, awareness of its existence is important to distinguish it from possible malignant mimics, such as lymphoepithelial carcinoma and metastatic mucoepidermoid carcinoma in a lymph node.

1 April 2009 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
LALaura Avila
Laura Avila
PSPonni Sivaprakasam
Ponni Sivaprakasam
SVSandra Viero
Sandra Viero
GSGino R. Somers
Gino R. Somers
MSMary Shago
Mary Shago
AGAbha Gupta
Abha Gupta

9 October 2025 in Histopathology
Verified
Journal Article
Open access
TTTrevor Teich
Trevor Teich
RHRong Hu
Rong Hu
ANAnita Nagy
Anita Nagy
MSMary Shago
Mary Shago
YKYen Chen Kevin Ko
Yen Chen Kevin Ko
EHElan Hahn
Elan Hahn
Aims: Immunohistochemistry (IHC) for p16 is widely used as a surrogate marker for HPV involvement in oropharyngeal squamous cell carcinoma (OPSCC), among other tumours. Confirming HPV status in OPSCC is critical, as HPV‐positive tumours have better overall survival and may require de‐escalated therapy compared to HPV‐independent OPSCC in the future. However, discordance exists between p16 and HPV, and direct HPV testing is occasionally required to ensure an accurate diagnosis. The aim of this study is to highlight the genomic basis behind the limitation of relying on p16 IHC as a surrogate marker for HPV involvement. Methods and Results: Through a multi‐institutional collaboration, this case series compiled four patients with a ‘false’ negative p16 staining pattern in HPV‐positive non‐keratinizing head and neck squamous cell carcinoma. All cases demonstrated minimal to no p16 IHC staining and were positive for HPV by direct RNA in situ hybridization. Through CDKN2A fluorescence in situ hybridization testing, three patients demonstrated a homozygous deletion of CDKN2A and one demonstrated a heterozygous deletion. Conclusions: This series highlights the genomic basis for the ‘false’ negative p16 results, raising awareness of a significant diagnostic pitfall while emphasizing the importance of careful consideration of clinicopathologic parameters in the clinical workup of these cases.